Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALX Oncology
Biotech
ALX's fizzling CD47 response rate sends stock spiraling down
After seeing its CD47 blocker easily beat control at an interim analysis, the biotech reported a much closer fight in the second half of the study.
Nick Paul Taylor
Aug 1, 2024 5:34am
ALX links CD47 drug to improved response rate in solid tumors
Oct 3, 2023 6:15am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
ALX follows Gilead in axing cancer trials as data disappoint
Aug 11, 2023 9:05am
After fast-tracking ALX's cancer hopeful, FDA pumps the brakes
Dec 7, 2020 9:35am
2 early-stage biotechs gun for $175M as IPO waters remain warm
Jun 29, 2020 7:20am
